Buy InVivoMAb Anti-Human EGFL7 Antibody (Iv0163)

Catalog No.

VHJ76201

Species reactivity

Human

Host species

Human

Isotype

IgG1, kappa

Clonality

Monoclonal

Target

NOTCH4-like protein, Zneu1, Multiple EGF-like domains protein 7, Epidermal growth factor-like protein 7, MEGF7, EGFL7, VE-statin, EGF-like protein 7, Multiple epidermal growth factor-like domains protein 7, Vascular endothelial statin

Concentration

1 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q9UHF1

Applications

ELISA, Neutralization, SPR

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Clone ID

Iv0163

The EGFL7-ITGB3-KLF2 axis enhances survival of multiple myeloma in preclinical models., PMID:32191808

EGFL7 Antagonizes NOTCH Signaling and Represents a Novel Therapeutic Target in Acute Myeloid Leukemia., PMID:31672772

Genetic Markers of the Host to Predict the Efficacy of Colorectal Cancer Targeted Therapy., PMID:31298142

EGFL7 - a potential therapeutic target for multiple sclerosis?, PMID:30312112

EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors., PMID:30065025

Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study., PMID:29636300

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with Carboplatin, Paclitaxel, and Bevacizumab for First-Line Nonsquamous Non-Small Cell Lung Cancer., PMID:29438092

Prognostic importance of circulating epidermal growth factor-like domain 7 in patients with metastatic colorectal cancer treated with chemotherapy and bevacizumab., PMID:28539619

Prognostic and biological significance of the proangiogenic factor EGFL7 in acute myeloid leukemia., PMID:28533390

Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer., PMID:28275117

Expression of Genes Involved in Vascular Morphogenesis and Maturation Predicts Efficacy of Bevacizumab-Based Chemotherapy in Patients Undergoing Liver Resection., PMID:27535973

MAGP2 controls Notch via interactions with RGD binding integrins: Identification of a novel ECM-integrin-Notch signaling axis., PMID:26808411

Expression of epidermal growth factor-like domain 7 correlates with clinicopathological features of osteosarcoma., PMID:26328008

Notching on Cancer's Door: Notch Signaling in Brain Tumors., PMID:25601901

Epidermal growth factor-like domain 7 predicts response to first-line chemotherapy and bevacizumab in patients with metastatic colorectal cancer., PMID:25140000

Real-time immuno-polymerase chain reaction in a 384-well format: detection of vascular endothelial growth factor and epidermal growth factor-like domain 7., PMID:25013989

Egfl7 is differentially expressed in arteries and veins during retinal vascular development., PMID:24595089

Anti-EGFL7 antibodies enhance stress-induced endothelial cell death and anti-VEGF efficacy., PMID:23945239

MicroRNA-126 and epidermal growth factor-like domain 7-an angiogenic couple of importance in metastatic colorectal cancer. Results from the Nordic ACT trial., PMID:23922111

CASZ1 promotes vascular assembly and morphogenesis through the direct regulation of an EGFL7/RhoA-mediated pathway., PMID:23639441

Human anti-EGFL7 recombinant full-length antibodies selected from a mammalian cell-based antibody display library., PMID:22297616

Notch: Implications of endogenous inhibitors for therapy., PMID:20486134

Document Download

InVivoMAb Anti-Human EGFL7 Antibody (Iv0163).pdf

InVivoMAb Anti-Human EGFL7 Antibody (Iv0163)